C-reactive protein (CRP) is a marker of infl ammation traditionally used as a complementary tool to support the clinical diagnosis and as a marker of severity of disease. CRP is an acute-phase protein synthesized by the liver after stimulus by cytokines and its serum levels increase markedly within hours after the onset of infection, infl ammation or tissue injury. Dynamic serial measurement of CRP has been widely used to help therapeutic decision-making. Decreasing plasma concentrations of this biomarker have been used as an indicator for resolution of infection or sepsis.
In the previous issue of Critical Care, Coelho and colleagues continued their longstanding work on Creactive protein (CRP) kinetics by evaluating the patterns of evolution of CRP in patients with severe communityacquired pneu monia (CAP) [1] . A time-dependent analysis was performed and CRP ratios were calculated daily in relation to the CRP concentration on day 0, considered equal to 1. Th ey showed that survivors of CAP had a continuous decrease of the CRP ratio during the fi rst week of antibiotic therapy. On the con trary, the CRP ratio remained elevated in non survivors. A value above 0.5 on day 5 was associated with a fi vefold increase in the risk of death in the ICU. Th ese data suggest that persistently elevated CRP values are indicative of poor response to antibiotic therapy in patients with CAP.
Serious infections and sepsis demand prompt and appropriate antimicrobial therapy. Many studies have shown the usefulness of serial measurements of CRP as a tool in the follow-up of diff erent conditions such as CAP [2] , ventilator-associated pneumonia [3] [4] [5] , bloodstream infection [6] and sepsis [7, 8] . Distinct patterns of CRP kinetics were related to diff erences in outcomes and/or appropriateness of antibiotic therapy.
Ineff ective empirical antimicrobial therapy or poor outcome was associated with increases in CRP concentrations in the fi rst 48 to 72 hours in patients with bloodstream infection or sepsis [6] [7] [8] , or with decreases to ratios <0.4 on the third day in patients with CAP [2] or <0.6 to 0.8 on the fourth day in patients with ventilatorassociated pneumonia [3] [4] [5] .
Th e kinetics of CRP may be modifi ed by age, genetic variability in the CRP gene, comorbidities, underlying conditions or therapeutic interventions other than antibiotics.
Th e use of CRP or other biomarkers is particularly important in older patients, who may have infection without fever, leucocytosis or other classical signs of infection. In older patients with very high CRP levels, infection was diagnosed in 75% of those with serum concentrations >5.0 mg/dl and in 94% of those with concentrations >10.0 mg/dl [9] . Minor increases in CRP concentrations may, however, represent subclinical illnesses such as cardiovascular diseases, cirrhosis, graft versus host disease, and systemic lupus erythematosus [10] [11] [12] . More elevated baseline plasma levels are associated with cancer [13] . In these conditions the persistence of high levels has suggested a complicated course, and a second increase is highly suggestive of an infectious complication. In septic critically ill cancer patients, CRP concentrations are more elevated in those with neutropenia [14] .
Th e incidence of deep venous thrombosis in a group of high-risk ICU patients receiving deep venous thrombosis prophylaxis is about 12% [15] . CRP also increases in patients with deep venous thrombosis. Th e acute-phase response is induced by the initial formation of thrombus, and a delayed presentation of deep venous thrombosis would allow time for CRP to return to normal levels [16] .
Transfusion of blood components is associated with an infl ammatory response. Approximately 70% of patients with an ICU length of stay longer than 1 week receive a blood transfusion [17] . A delay in the decline of or no decline in CRP serum levels during the morning following transfusion must therefore be expected [18] .
Conversely, some circumstances are expected to lower CRP levels. Glucocorticoids are the most important physiologic inhibitors of infl ammation. Patients with acute respiratory distress syndrome treated with methylpredinisolone showed a signifi cant reduction in CRP levels in comparison with those not receiving the drug [19] . CRP is more a marker of severe liver dysfunction than infection in patients with acute hepatic failure. Severe hepatic failure should be ruled out in patients with a high suspicion of infection and an abnormally low CRP concentration or with a marked CRP decline despite persistent septic shock [20] .
Hence, failure of CRP levels to fall after 5 days should address additional investigation for inadequate antibiotic therapy, unrevealing resistant infection or localized pus, new infection or serious noninfectious pathology such as thrombosis or cancer. Th e usefulness of CRP as a surrogate of response to therapy has been widely studied. Use of CRP to guide the duration of antibiotic therapy and the potential of the combination of several biomarkers refl ecting diff erent pathophysiological pathways in improving the management of infections remain to be investigated.
Abbreviations CAP, community-acquired pneumonia; CRP, C-reactive protein.
